. Autophagy: A common mechanism of intrinsic (primary) and acquired (secondary) resistance to trastuzumab. Images show representative portions of trastuzumab-sensitive SKBR3 cells, trastuzumab-refractory SKBR3 cells (i.e., SKBR3/TzbR cells, which were obtained by continuously culturing SKBR3 parental cells in the presence of high-dose trastuzumab44, and trastuzumab-JIMT-1 cell cultures in the absence or presence of 100 g/mL trastuzumab (48 h) that were captured using different channels for LC3 (red), p62 (green), and Hoechst 33258 (blue) with a 20× objective and merged on a BD PathwayTM 855 Bioimager System using BD AttovisionTM software. Scale bar=25 µm. When considering overlapping fluorescence of LC3 and p62/SQSTM1 as an indirect marker of p62/SQSTM1 presenting ubiquitinated protein bodies to the autophagic machinery in an LC3-dependent manner, SKBR3/TzbR cells with acquired (secondary) resistance to trastuzumab displayed a comparable autophagic flux to that observed in JIMT-1 cells with intrinsic (primary) resistance to trastuzumab.
Supplementary Figure 2. Trastuzumab-refractory JIMT-1 cells have high levels of basal autophagy. Trastuzumab-refractory
JIMT-1 cells and trastuzumab-responsive SKBR3 cells were infected with a retrovirus expressing GFP-LC3, grown in complete media in the presence of serum in the absence or presence of trastuzumab (72 h), and then fixed and analyzed by fluorescence microscopy for the presence of LC3 puncta, which represent autophagic vesicles. Numerous discrete autophagic puncta were present in trastuzumab-refractory JIMT-1 cells, while trastuzumab-responsive SKBR3 cells showed only a diffuse expression of GFP. Note the further increase of autophagic cells (defined as the presence of more than five foci) in the presence of trastuzumab. Figure 3 . Genetic ablation of the autophagy machinery: Impact on chemotherapy efficacy in HER2 geneamplified breast cancer cells with primary resistance to HER targeting drugs. The metabolic status of JIMT-1 parental (WT), control shRNA-JIMT-1, and ATG8/LC3 shRNA-JIMT-1 cells treated with graded concentrations of doxorubicin (DOX), 5-fluorouracil (5-FU), cisplatin (CDDP), vinorelbine (VNR), and paclitaxel (PTX) was evaluated using MTT-based cell viability assays, followed by the generation of dose-response graphs depicting the % of untreated cells (untreated control cells=100% cell viability; figures not shown). Bars representing mean IC50 values in each cell line illustrate the degree of sensitivity to cytotoxics. Error bars show 95% confidence intervals of three independent experiments performed in triplicate. Note the lack of significant reductions in the cytotoxics IC50 values in response to genetic ablation of the autophagic machinery in trastuzumab-refractory JIMT-1 cells.
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